A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) with talazoparib (BMN 673) in HRRD Medivation (MDVN)-positive patients. SECONDARY OBJECTIVES: I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survi...

Full description

Bibliographic Details
Other Involved Persons: Southwest Oncology Group
Format: eBook
Published: Bethesda (Maryland) : ClinicalTrials.gov September 9, 2019
Item Description:Copyright: Source: ClinicalTrials.gov (no modifications made)
Copyright: ClinicalTrials.gov processed this data on December 13, 2019
Copyright: Last update posted on ClinicalTrials.gov: September 9, 2019
Copyright: Last updated: 2019-12-16
Physical Description:Online-Ressource
QR Code: Show QR Code